Marty Stanton
Advisory
aptamer technology
AptSciÂ
Korea
Biography
Dr. Stanton is an expert in aptamer technology who has held leadership positions in both SomaLogic and Archemix. Dr. Stanton was the CSO and COO at SomaLogic, where he led the development of SomaLogic’s aptamer-based biomarker discovery platform. In 2001, Dr. Stanton co-founded Archemix Corp., a biopharmaceutical developing aptamer therapeutics. Dr. Stanton has also held a number of other positions in the biopharmaceutical industry, including: President of Dexela Ltd., a company developing three-dimensional medical imaging for the early detection of cancer; and CSO of BiOptix, a company developing novel label-free instrumentation for diagnostic and research applications.
Research Interest
Dr. Stanton is an expert in aptamer technology who has held leadership positions in both SomaLogic and Archemix. Dr. Stanton was the CSO and COO at SomaLogic, where he led the development of SomaLogic’s aptamer-based biomarker discovery platform. In 2001, Dr. Stanton co-founded Archemix Corp., a biopharmaceutical developing aptamer therapeutics. Dr. Stanton has also held a number of other positions in the biopharmaceutical industry, including: President of Dexela Ltd., a company developing three-dimensional medical imaging for the early detection of cancer; and CSO of BiOptix, a company developing novel label-free instrumentation for diagnostic and research applications.
